{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T11:47:41Z","timestamp":1765540061129,"version":"3.48.0"},"reference-count":14,"publisher":"Walter de Gruyter GmbH","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_jbcpp-2023-0051_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The use of Bruton\u2019s tyrosine kinase (BTK) inhibitors has changed the clinical history of patients with chronic lymphocytic leukemia (CLL) in both na\u00efve and relapsed\/refractory settings. \u201cAccelerated\u201d chronic lymphocytic leukemia (a-CLL) is a relatively rare form of CLL representing less than 1\u00a0% of all CLL cases. a-CLL patients usually have a more aggressive course and a reduced overall survival was reported with conventional chemo-immunotherapy approaches.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jbcpp-2023-0051_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The role of Bruton Tyrosine Kinase-inhibitor, ibrutinib, in a-CLL is well established with encouraging preliminary results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jbcpp-2023-0051_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We report a case of a-CLL-treated first-line with second-generation BTKi, acalabrutinib with a prompt clinical response. As known, it is the first literature report on acalabrutinib in a-CLL highlighting the role of second-generation BTKi also in this high-risk setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jbcpp-2023-0051_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Target therapies (Bruton Kinase inhibitors and Bcl2 inhibitors) have improved the therapeutic landscape of CLL. The availability of therapeutic targets requires greater diagnostic accuracy to choose the most appropriate therapy for each patient.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/jbcpp-2023-0051","type":"journal-article","created":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T13:59:49Z","timestamp":1681221589000},"page":"401-404","source":"Crossref","is-referenced-by-count":3,"title":["The role of Bruton\u2019s kinase inhibitors (BTKi) in accelerated Chronic Lymphocytic Leukemia (a-CLL): a case of successful response to acalabrutinib"],"prefix":"10.1515","volume":"34","author":[{"given":"Gioacchino","family":"Catania","sequence":"first","affiliation":[{"name":"Struttura Complessa di Ematologia a Direzione Universitaria, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo , Alessandria , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Tavarozzi","sequence":"additional","affiliation":[{"name":"Struttura Complessa di Ematologia a Direzione Universitaria, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo , Alessandria , Italy"},{"name":"Department of Translational Medicine , University of Eastern Piedmont , Novara , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giacomo Maria","family":"Pini","sequence":"additional","affiliation":[{"name":"Department of Pathology , Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo , Alessandria , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiziana","family":"Borra","sequence":"additional","affiliation":[{"name":"Department of Pathology , Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo , Alessandria , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Gandolfo","sequence":"additional","affiliation":[{"name":"Struttura Complessa di Ematologia a Direzione Universitaria, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo , Alessandria , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Zacchi","sequence":"additional","affiliation":[{"name":"Struttura Complessa di Ematologia a Direzione Universitaria, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo , Alessandria , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Pietrasanta","sequence":"additional","affiliation":[{"name":"Struttura Complessa di Ematologia a Direzione Universitaria, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo , Alessandria , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Monaco","sequence":"additional","affiliation":[{"name":"Struttura Complessa di Ematologia a Direzione Universitaria, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo , Alessandria , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuela","family":"Zanni","sequence":"additional","affiliation":[{"name":"Struttura Complessa di Ematologia a Direzione Universitaria, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo , Alessandria , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maddalena","family":"Lettieri","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences , University Federico II , Naples , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Rivela","sequence":"additional","affiliation":[{"name":"Struttura Complessa di Ematologia a Direzione Universitaria, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo , Alessandria , Italy"},{"name":"Department of Translational Medicine , University of Eastern Piedmont , Novara , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Zallio","sequence":"additional","affiliation":[{"name":"Struttura Complessa di Ematologia a Direzione Universitaria, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo , Alessandria , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Ladetto","sequence":"additional","affiliation":[{"name":"Struttura Complessa di Ematologia a Direzione Universitaria, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo , Alessandria , Italy"},{"name":"Department of Translational Medicine , University of Eastern Piedmont , Novara , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2023,4,12]]},"reference":[{"key":"2025121209104184610_j_jbcpp-2023-0051_ref_001","doi-asserted-by":"crossref","unstructured":"Kipps, TJ, Stevenson, FK, Wu, CJ, Croce, CM, Packham, G, Wierda, WG, et al.. Chronic lymphocytic leukaemia. Nat Rev Dis Prim 2017;3:16096. https:\/\/doi.org\/10.1038\/nrdp.2016.96.","DOI":"10.1038\/nrdp.2016.96"},{"key":"2025121209104184610_j_jbcpp-2023-0051_ref_002","doi-asserted-by":"crossref","unstructured":"Hallek, M. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment. Am J Hematol 2019;94:1266\u201387. https:\/\/doi.org\/10.1002\/ajh.25595.","DOI":"10.1002\/ajh.25595"},{"key":"2025121209104184610_j_jbcpp-2023-0051_ref_003","doi-asserted-by":"crossref","unstructured":"THerndon, TM, Chen, SS, Saba, NS, Valdez, J, Emson, C, Gatmaitain, M, et al.. Direct in\u00a0vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood. Leuk 2017;31:1340\u20137. https:\/\/doi.org\/10.1038\/leu.2017.11.","DOI":"10.1038\/leu.2017.11"},{"key":"2025121209104184610_j_jbcpp-2023-0051_ref_004","doi-asserted-by":"crossref","unstructured":"Gine, E, Martinez, A, Villamor, N, Lopez-Guillermo, A, Camos, M, Martinez, J, et al.. Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia (\u201caccelerated\u201d chronic lymphocytic leukemia) with aggressive clinical behavior. Haematologica 2010;95:1526\u201333. https:\/\/doi.org\/10.3324\/haematol.2009.022277.","DOI":"10.3324\/haematol.2010.022277"},{"key":"2025121209104184610_j_jbcpp-2023-0051_ref_005","doi-asserted-by":"crossref","unstructured":"Xie, J, Jang, A, Vegel, A, Hajja, Y, Mouawad, Y, Baghiani, A, et al.. Successful treatment of \u201caccelerated\u201d chronic lymphocytic leukemia with single agent ibrutinib: a report of two cases. Leukemia Res Rep 2021;15:100247. https:\/\/doi.org\/10.1016\/j.lrr.2021.100247.","DOI":"10.1016\/j.lrr.2021.100247"},{"key":"2025121209104184610_j_jbcpp-2023-0051_ref_006","doi-asserted-by":"crossref","unstructured":"Robak, T, Witkowska, M, Smolewski, P. The role of Bruton\u2019s kinase inhibitors in chronic lymphocytic leukemia: current status and future directions. Cancers 2022;14:771.","DOI":"10.3390\/cancers14030771"},{"key":"2025121209104184610_j_jbcpp-2023-0051_ref_007","doi-asserted-by":"crossref","unstructured":"Lewis, KL, Cheah, CYJ. Non-covalent BTK inhibitors-the new BTKids on the block for B-cell malignancies. Pers Med 2021;11:764. https:\/\/doi.org\/10.3390\/jpm11080764.","DOI":"10.3390\/jpm11080764"},{"key":"2025121209104184610_j_jbcpp-2023-0051_ref_008","doi-asserted-by":"crossref","unstructured":"Mato, AR, Shah, NN, Jurczak, W, Cheah, CY, Pagel, JM, Woyach, JA, et al.. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study. Lancet 2021;397:892\u2013901. https:\/\/doi.org\/10.1016\/s0140-6736(21)00224-5.","DOI":"10.1016\/S0140-6736(21)00224-5"},{"key":"2025121209104184610_j_jbcpp-2023-0051_ref_009","doi-asserted-by":"crossref","unstructured":"Binnerts, ME, Otipoby, KL, Hopkins, BT, Bohnert, T, Hansen, S, Jamieson, G, et al.. SNS-062 is a potent noncovalent BTK inhibitor with comparable activity against wide type BTK and BTK with an acquired resistance mutation. Mol Cancer Therapeut 2015;14:C186. https:\/\/doi.org\/10.1158\/1535-7163.targ-15-c186.","DOI":"10.1158\/1535-7163.TARG-15-C186"},{"key":"2025121209104184610_j_jbcpp-2023-0051_ref_010","doi-asserted-by":"crossref","unstructured":"Shanafelt, TD, Wang, XV, Kay, NE, Curtis, A, O\u2019Brien, S, Barrientos, J, et al.. Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med 2019;381:432\u201343.","DOI":"10.1056\/NEJMoa1817073"},{"key":"2025121209104184610_j_jbcpp-2023-0051_ref_011","doi-asserted-by":"crossref","unstructured":"Sharman, JP, Egyed, M, Jurczak, W, Skarbnik, A, Pagel, JM, Flinn, IW, et al.. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE .R.,TN): a randomised, controlled, phase 3 trial. Lancet 2020;395:1278\u201391. https:\/\/doi.org\/10.1016\/s0140-6736(20)30262-2.","DOI":"10.1016\/S0140-6736(20)30262-2"},{"key":"2025121209104184610_j_jbcpp-2023-0051_ref_012","doi-asserted-by":"crossref","unstructured":"Ghia, P, Pluta, A, Wach, M, Lysak, D, Kozak, T, Simkovic, M, et al.. ASCEND: phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 2020;38:2849\u201361. https:\/\/doi.org\/10.1200\/jco.19.03355.","DOI":"10.1200\/JCO.19.03355"},{"key":"2025121209104184610_j_jbcpp-2023-0051_ref_013","doi-asserted-by":"crossref","unstructured":"Byrd, JC, Hillmen, P, Ghia, P, Kater, AP, Chanan-Khan, A, Furman, R, et al.. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol 2021;39:3441\u201352. https:\/\/doi.org\/10.1200\/jco.21.01210.","DOI":"10.1200\/JCO.21.01210"},{"key":"2025121209104184610_j_jbcpp-2023-0051_ref_014","doi-asserted-by":"crossref","unstructured":"Condoluci, A, Rossi, D. Biology and treatment of Richter transformation. Front Oncol 2022;12:829983. https:\/\/doi.org\/10.3389\/fonc.2022.829983.","DOI":"10.3389\/fonc.2022.829983"}],"container-title":["Journal of Basic and Clinical Physiology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jbcpp-2023-0051\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jbcpp-2023-0051\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T11:43:55Z","timestamp":1765539835000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jbcpp-2023-0051\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,12]]},"references-count":14,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3,20]]},"published-print":{"date-parts":[[2023,5,8]]}},"alternative-id":["10.1515\/jbcpp-2023-0051"],"URL":"https:\/\/doi.org\/10.1515\/jbcpp-2023-0051","relation":{},"ISSN":["0792-6855","2191-0286"],"issn-type":[{"type":"print","value":"0792-6855"},{"type":"electronic","value":"2191-0286"}],"subject":[],"published":{"date-parts":[[2023,4,12]]}}}